KRAS G12C drugs for Non-Small Cell Lung Cancer
13 tracked KRAS G12C drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the KRAS G12C page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 approved / phase 46 Phase 31 Phase 22 Phase 1/22 Phase 1
Head-to-head evidence: Adagrasib vs BBO-8520 · Adagrasib vs Calderasib · Adagrasib vs Divarasib · Adagrasib vs Elironrasib · Adagrasib vs FMC-376 · Adagrasib vs Fulzerasib